13175-00-3

Usage

Uses

Used in Pharmaceutical Industry:
2-Methyl-2H-tetrazole-5-carboxylic acid is used as a synthetic intermediate for the development of various pharmaceuticals. Its unique chemical structure allows it to be a key component in the creation of new drugs, contributing to the advancement of medicine and healthcare.
Used in Chemical Industry:
In the chemical industry, 2-Methyl-2H-tetrazole-5-carboxylic acid is utilized as a building block for the synthesis of other organic compounds. Its versatility in chemical reactions makes it an essential substance for the production of a wide range of chemical products, from specialty chemicals to everyday consumer goods.
Used in Research and Development:
2-Methyl-2H-tetrazole-5-carboxylic acid is employed as a research compound in scientific studies and experiments. Its reactivity and potential applications in various fields make it a valuable tool for researchers working on new discoveries and innovations in chemistry and related disciplines.

InChI:InChI=1/C3H4N4O2/c1-7-5-2(3(8)9)4-6-7/h1H3,(H,8,9)

Upstream product

• 91511-39-6 2-methyl-2H-tetrazole-5-carbonitrile 
• 55408-10-1 1H-tetrazole-5-carboxylic acid ethyl ester 
• 74-88-4 methyl iodide 
• 91511-38-5 ethyl 2-methyl-2H-tetrazole-5-carboxylate 
• 91616-41-0 ethyl 1-methyl-1H-tetrazole-5-carboxylate 

Downstream Products

• 64591-58-8 (2-methyl-2H-tetrazol-5-yl)-phenyl-methanone 
• 96107-88-9 methyl 2-methyl-2H-tetrazole-5-carboxylate 
• 91511-38-5 ethyl 2-methyl-2H-tetrazole-5-carboxylate 
• 16681-78-0 2-methyltetrazole 

Relevant academic research and scientific papers

Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy

Hypercontractility of the cardiac sarcomere may be essential for the underlying pathological hypertrophy and fibrosis in genetic hypertrophic cardiomyopathies. Aficamten (CK-274) is a novel cardiac myosin inhibitor that was discovered from the optimization of indoline compound 1. The important advancement of the optimization was discovery of an Indane analogue (12) with a less restrictive structure-activity relationship that allowed for the rapid improvement of drug-like properties. Aficamten was designed to provide a predicted human half-life (t1/2) appropriate for once a day (qd) dosing, to reach steady state within two weeks, to have no substantial cytochrome P450 induction or inhibition, and to have a wide therapeutic window in vivo with a clear pharmacokinetic/pharmacodynamic relationship. In a phase I clinical trial, aficamten demonstrated a human t1/2 similar to predictions and was able to reach steady state concentration within the desired two-week window.

DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS

Provided are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt, thereof for use in methods of treatment heart diseases through cardiac sarcomere inhibtion.

HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS

A compound represented by the formula (I): wherein Z1,Z2,Z3 and Z4 are the following combination, (Z1,Z2,Z3,Z4)=(CR4,N,CR5,C), (N,N,CR5,C), (N,C,CR5,N), (S,C,CR5,C) or (S,C,N,C); R1 and R2 are the same or different and each is (1) a hydrogen atom, (2) a halogen atom, (3) a group bonded via a carbon atom, (4) a group bonded via a nitrogen atom, (5) a group bonded via an oxygen atom or (6) a group bonded via a sulfur atom; R 3 is an amino optionally having substituent(s); R4 and R 5 are the same or different and each is (1) a hydrogen atom, (2) a halogen atom, (3) a group bonded via a carbon atom, (4) a group bonded via a nitrogen atom, (5) a group bonded via an oxygen atom or (6) a group bonded via a sulfur atom; R3 and R4 optionally form a ring optionally having substituent(s); and a group represented by the formula (A) is a cyclic group optionally having substituent(s), or a salt thereof

QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS

The present invention relates to novel quinolones of Formula I that inhibit inducible NOS synthase together with methods of synthesizing and using the compounds including methods for inhibiting or modulating nitric oxide synthesis and/or lowering nitric oxide levels in a patient by administering the compounds for the treatment of disease.

Positional Selectivity of the Methylation of 5-Substituted Tetrazolate Anions

The methylation of a series of 15 sodium 5-substituted tetrazolates using iodomethane in acetone/water (4:1) has been studied.The reaction yields both 1- and 2-methyl products, and the ratio of these products is discussed in terms of the nature of the 5-substituent.Electronic and steric effects dominate the reaction pathway; both increased substituent electronegativity and steric bulk lead to predominant methylation at N 2.Sodium 5-ethoxycarbonyltetrazolate (3n) goes against this trend and an intermediate is proposed where the incoming electrophile is associated with the ester carbonyl group.